Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Analgecine for Neuropathic Pain
NCT02633618Phase 3Completed
- Sponsor
- Vanworld Pharmaceutical (Rugao) Co., Ltd.
- Start
- Aug 2005
- Primary completion
- Dec 2005
- Modality
- Biologic
01
Overview
Phase 3, randomised, open-label trial of Analgecine in neuropathic pain (2 arms), sponsored by Vanworld Pharmaceutical (Rugao) Co., Ltd. Primary endpoint: Change of Visual Analog Scale on Pain at 2 weeks. Started Aug 2005; status: completed.
02
Drugs
Analgecine
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT02633618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633618.